ER+ or HER2+ breast cancers have low mutational burden, low PD-L1 expression, defective antigen processing/presentation, and an immunosuppressive tumor microenvironment (TME), making them refractile to ICB. This evidence concerns the gene ERBB2 and breast cancer.